<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><description>乘之愈往，识之愈真。如将不尽，与古为新。</description><managingEditor> (hellodword)</managingEditor><pubDate>Sat, 24 Apr 2021 07:24:33 +0800</pubDate><image><url>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</url><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>FDA批准CD19 ADC药物，瓴路药业拥有中国权益</title><link>https://mp.weixin.qq.com/s/TjDmw5kR0ET6NQkUVi1ciw</link><description></description><content:encoded><![CDATA[FDA批准CD19 ADC药物，瓴路药业拥有中国权益]]></content:encoded><pubDate>Sat, 24 Apr 2021 06:49:35 +0800</pubDate></item><item><title>柳叶刀：索马鲁肽与Amylin联用，减重效果翻倍</title><link>https://mp.weixin.qq.com/s/OCo5QPgKMCMZPhCztHayWQ</link><description></description><content:encoded><![CDATA[柳叶刀：索马鲁肽与Amylin联用，减重效果翻倍]]></content:encoded><pubDate>Sat, 24 Apr 2021 06:49:35 +0800</pubDate></item><item><title>FDA批准第4款PD-1抗体：葛兰素史克Dostarlimab，药明生物提供CMO服务</title><link>https://mp.weixin.qq.com/s/aWQ2CYp_Wsl7UXtIX7lt5w</link><description></description><content:encoded><![CDATA[FDA批准第4款PD-1抗体：葛兰素史克Dostarlimab，药明生物提供CMO服务]]></content:encoded><pubDate>Fri, 23 Apr 2021 12:18:33 +0800</pubDate></item><item><title>健艾仕新药申报临床：GEC-255</title><link>https://mp.weixin.qq.com/s/z8r-fkB9f022r5G8bO7ZxQ</link><description></description><content:encoded><![CDATA[健艾仕新药申报临床：GEC-255]]></content:encoded><pubDate>Fri, 23 Apr 2021 12:18:33 +0800</pubDate></item><item><title>国内第2款：维立志博申报PD-1/TGFβ双抗</title><link>https://mp.weixin.qq.com/s/_GNhQerSi79rYMZaz1s1bw</link><description></description><content:encoded><![CDATA[国内第2款：维立志博申报PD-1/TGFβ双抗]]></content:encoded><pubDate>Fri, 23 Apr 2021 12:18:33 +0800</pubDate></item><item><title>海普瑞申报卵巢癌抗体疫苗Oregovomab</title><link>https://mp.weixin.qq.com/s/hQ4JeYjIW7OKNI-_f_9lZA</link><description></description><content:encoded><![CDATA[海普瑞申报卵巢癌抗体疫苗Oregovomab]]></content:encoded><pubDate>Fri, 23 Apr 2021 12:18:33 +0800</pubDate></item><item><title>宜明昂科申报HER2/CD47双抗</title><link>https://mp.weixin.qq.com/s/8s2sbqMWbVAnoK5koLH-YA</link><description></description><content:encoded><![CDATA[宜明昂科申报HER2/CD47双抗]]></content:encoded><pubDate>Fri, 23 Apr 2021 12:18:33 +0800</pubDate></item><item><title>复旦张江申报Trop2 ADC，国内第5家</title><link>https://mp.weixin.qq.com/s/aj0MMBmuM6uVZdUv_G0acA</link><description></description><content:encoded><![CDATA[复旦张江申报Trop2 ADC，国内第5家]]></content:encoded><pubDate>Thu, 22 Apr 2021 06:48:33 +0800</pubDate></item><item><title>ADCC：抗体药体外免疫活性质检标杆</title><link>https://mp.weixin.qq.com/s/NavCyCmrOl6NroFFiBeL_A</link><description></description><content:encoded><![CDATA[ADCC：抗体药体外免疫活性质检标杆]]></content:encoded><pubDate>Thu, 22 Apr 2021 06:48:33 +0800</pubDate></item><item><title>非小细胞肺癌靶向治疗新时代</title><link>https://mp.weixin.qq.com/s/eOQN5wX6EJwirdrKxBagnA</link><description></description><content:encoded><![CDATA[非小细胞肺癌靶向治疗新时代]]></content:encoded><pubDate>Wed, 21 Apr 2021 11:09:37 +0800</pubDate></item><item><title>最优BTK抑制剂出炉：诺诚健华奥布替尼</title><link>https://mp.weixin.qq.com/s/ccxwb9QF2KYQsIrhOYwC9A</link><description></description><content:encoded><![CDATA[最优BTK抑制剂出炉：诺诚健华奥布替尼]]></content:encoded><pubDate>Wed, 21 Apr 2021 11:09:37 +0800</pubDate></item><item><title>缺氧诱导CAR-T：解决on target/off-tumor毒性</title><link>https://mp.weixin.qq.com/s/Nkx1FHAd-whuOrelHmN_aQ</link><description></description><content:encoded><![CDATA[缺氧诱导CAR-T：解决on target/off-tumor毒性]]></content:encoded><pubDate>Wed, 21 Apr 2021 11:09:37 +0800</pubDate></item><item><title>多弹头ADC：华东医药入股诺灵生物</title><link>https://mp.weixin.qq.com/s/Zn7feLCyOVvq25cn0vW06Q</link><description></description><content:encoded><![CDATA[多弹头ADC：华东医药入股诺灵生物]]></content:encoded><pubDate>Tue, 20 Apr 2021 07:17:58 +0800</pubDate></item><item><title>Agenus递交PD-1抗体上市申请，贝达药业拥有中国权益</title><link>https://mp.weixin.qq.com/s/FPKXMswFz2eLr1MFujmexA</link><description></description><content:encoded><![CDATA[Agenus递交PD-1抗体上市申请，贝达药业拥有中国权益]]></content:encoded><pubDate>Tue, 20 Apr 2021 07:17:58 +0800</pubDate></item><item><title>AACR：中国声音</title><link>https://mp.weixin.qq.com/s/iBsfd9clzSxt-2ns8wBA-g</link><description></description><content:encoded><![CDATA[AACR：中国声音]]></content:encoded><pubDate>Mon, 19 Apr 2021 14:26:47 +0800</pubDate></item><item><title>NextCure下一站：B7-H4</title><link>https://mp.weixin.qq.com/s/WxdP6NAGzDAb4gIW5xfPEA</link><description></description><content:encoded><![CDATA[NextCure下一站：B7-H4]]></content:encoded><pubDate>Sun, 18 Apr 2021 14:41:54 +0800</pubDate></item><item><title>一线胃癌首个免疫疗法：Opdivo获FDA批准</title><link>https://mp.weixin.qq.com/s/bvsuUXUTKfkfKBBQuv2yiQ</link><description></description><content:encoded><![CDATA[一线胃癌首个免疫疗法：Opdivo获FDA批准]]></content:encoded><pubDate>Sat, 17 Apr 2021 06:55:36 +0800</pubDate></item><item><title>AACR：细胞因子新时代</title><link>https://mp.weixin.qq.com/s/uvNLFwRK6n5ZDBy2n_tnWA</link><description></description><content:encoded><![CDATA[AACR：细胞因子新时代]]></content:encoded><pubDate>Fri, 16 Apr 2021 06:59:16 +0800</pubDate></item><item><title>AACR：日新月异的ADC</title><link>https://mp.weixin.qq.com/s/WwvwnGgmVl_7H5ThwKyjwg</link><description></description><content:encoded><![CDATA[AACR：日新月异的ADC]]></content:encoded><pubDate>Thu, 15 Apr 2021 06:46:56 +0800</pubDate></item></channel></rss>